Articles
04.10.2021
Good value propositions

We outline the 3 key components of a good value proposition, designed to demonstrate the value of ne...

Read more
Articles
22.09.2021
Commercial arrangements in access to medicine

The introduction of new medicines in England requires the cooperation of industry and the NHS.

Read more
Articles
20.09.2021
Improving patient engagement

NICE is increasing opportunities for patient engagement by simplifying the process and increasing pa...

Read more
News
09.09.2021
PMA Insights: Week 39 2021

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
06.09.2021
Strategies to navigate patent expiry

Patents are usually only valid for around 20 years however, as patenting occurs early in the R&D pro...

Read more
Articles
06.09.2021
Real world evidence

Real-world evidence (RWE) refers to clinical and economic evidence which has been derived from the a...

Read more
Articles
01.09.2021
England's new integrated care systems

Integrated Care Systems (ICS) have been designed to enable health and care organisations to join for...

Read more
Articles
30.08.2021
Blockbuster drugs of the next decade

Until June 30th, 2021, the FDA in the US and European Medicine Agency in Europe have launched 32 and...

Read more
Articles
06.08.2021
Healthcare performance comparison summary

The Common Wealth Fund has recently released a healthcare performance comparison report between 11 c...

Read more
Articles
04.08.2021
ICER puts spotlight on health insurers

ICER recently outlined its plans to annually assess Barriers to Fair Access within prescription drug...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.